+ 1 888 391 5441

Investigation Report on China's Repaglinide Market, 2018-2022



Since the 1980s, China's economic development has improved living standards and urbanization level, which significantly increases the incidence of obesity, diabetes and other non-communicable diseases in China. And population aging and other factors sharply raise the incidence of type 2 diabetes. The number of type 2 diabetic patients in China surpassed 110 million at the end of 2017, and is growing by 1.5 million to 2 million every year.

Insulin secretagogues are mainly used to treat type 2 diabetes. Compared with sulfonylureas, insulin secretagogues have short-lasting effects and cause few hypoglycemia reactions.

Developed by Danish company Novo Nordisk and German company Boehringer Ingelheim, Repaglinide is a non-sulfonylurea-based insulin secretagogue used to control postprandial hyperglycemia. The drug was launched in the U.S. in Apr.1998. Entering China in 2000, Novo Nordisk's NovoNorm has few competitors. According to CRI's market research, by sales value, the market share of Novo Nordisk was about 80% in 2017, while the market share of Jiangsu Hansoh Pharmaceutical Co., Ltd., its major competitor, was less than 20%. But Novo Nordisk's market share is sliding because NovoNorm is more expensive than China-made generic drugs. In 2017, the sales value of Repaglinide was about CNY 272 million in China, representing a slow decline from 2013 to 2017. Considering good efficacy, reasonable prices, and the increasing number of type 2 diabetic patients, Repaglinide will still have certain growth potential in China in the next few years.

Topics Covered:

  • Situation of type 2 diabetes in China
  • Size of China's Repaglinide market
  • Major Repaglinide manufacturers in China
  • Competition on China's Repaglinide market
  • Retail prices of Repaglinide in China
  • Prospect of China's Repaglinide market from 2018 to 2022
Why http://www.chinamarketresearchreports.com

Investigation Report on China's Repaglinide Market, 2018-2022


Related reports :

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy